Molecular Profile Detail

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT Q575_P577delinsH	thymus squamous cell carcinoma	predicted - sensitive	KIT Inhibitor	Lenvatinib	Case Reports/Case Series	Actionable	In a clinical case study, Lenvima (lenvatinib) treatment resulted in a partial response with treatment lasting 10 months in a patient with metastatic thymic squamous cell carcinoma harboring KIT Q575_P577delinsH (PMID: 38706977).	38706977
KIT Q575_P577delinsH	gastrointestinal stromal tumor	predicted - sensitive	KIT Inhibitor	Imatinib	Case Reports/Case Series	Actionable	In a clinical study, Gleevec (imatinib) treatment resulted in partial responses in 2 patients with metastatic rectal gastrointestinal stromal tumor harboring germline KIT Q575_P577delinsH, with treatment ongoing for at least 58 months in one patient and disease stabilization ongoing for at least 12 months in the second patient (PMID: 18183595).	18183595

Profile Name	KIT Q575_P577delinsH
Gene Variant Detail	KIT Q575_P577delinsH (gain of function - predicted)
Relevant Treatment Approaches	KIT Inhibitor